ClinicalThought
View More
Read my take on NASH heterogeneity and its implications for treatment.
Those who treat patients with type 2 diabetes may encounter nonalcoholic fatty liver disease. See an expert’s summary of guideline-recommended management and how we can better care for these patients.
An expert shares her take on emerging strategies for combination treatment for NAFLD and NASH with GLP-1 receptor agonists plus SGLT2 inhibitors.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.